Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

DaVita buys HealthCare Partners. Boston Scientific/Philips imaging collaboration. More news briefs.

You may also be interested in...



People Briefs: Appointments At Covidien, Stryker, DaVita, InspireMD, JDRF

Covidien expands group president Bryan Hanson’s portfolio to include all business units. Stryker adds board chairmen role for CEO Kevin Lobo. More people news.

Waiting For Exhale: Emphysema Researchers Call For New Stent Designs, More Analysis

New stent designs and placement techniques are needed to develop an interventional device that successfully treats severe emphysema, researchers said following publication of disappointing study results for a drug-eluting stent system intended to create airway passages in the lung.

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel